SOUTH SAN FRANCISCO, Nov. 19, 2025 — In March this year, South San Francisco-based Twist Bioscience announced that for a limited time all Twist Express Genes orders placed by academic customers globally will be shipped in as few as four days without incurring a premium for the rapid turnaround time.

 

The announcement aligns with the focus of this mid-cap growth and value equity company, which aims to serve customers making a positive impact on the world.

 

Beyond functioning as a platform for voluntary-oriented work, Twist Bioscience has secured a strong strategic position.

 

Being a company that has pioneered the life sciences segment of the health care sector, Twist Bioscience, along with Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, announced in May this year that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. New terms provide Twist with a key license to long DNA technology and assets. Ginkgo will continue ordering from Twist with no purchase minimums.

 

A few weeks later, after announcing its renewed collaboration with Ginkgo, Twist Bioscience declared the DNA data storage business as an independent company.

 

‘There are many applications of synthetic DNA with the potential to have an incredible impact on the world. With this spin-out, both Twist and Atlas are able to move with full force in growing those applications,’ said Emily M. Leproust, Ph.D., CEO and co-founder of Twist.

 

A Hamilton Health Sciences, or HHS, research lab that studies DNA and genetic information became in May the first and only Canadian lab to earn certification as a next-generation sequencing professional laboratory, or NGS ProLab service provider, from Twist Bioscience, a global leader in synthetic biology. In fields such as medicine, agriculture, and industrial chemicals, customers using Twist Bioscience’s synthetic DNA tools are developing ways to improve lives and enhance the sustainability of the planet.

 

‘The faster our customers succeed, the better for the world, and Twist Bioscience is uniquely positioned to help accelerate these efforts. We have created a revolutionary silicon platform that offers precision at a scale unavailable anywhere else,’ says the company website.

 

Know More about High-Quality, Faster Synthetic DNA

 

Genes Segment: The innovative method of DNA production at Twist Bioscience enables the manufacture of high-quality synthetic DNA faster and more affordably than ever before. It also rolls out high-throughput synthesis that is highly scalable and fully customizable. The realization of scientific opportunities at unprecedented speed is a unique aspect of Twist Bioscience. The company plays a key role in cancer research and drug discovery.

 

In the genes segment, Twist Bioscience offers Vectors, Multiplexed Gene Fragments, Express Genes, Clonal Genes, and Gene Fragments. The continuing focus at this biotech company ensures that molecular biology and cloning do not become a bottleneck in research.

 

Twist Bioscience has established extensive TCR libraries. Adoptive cell therapy, or ACT, has led to highly effective cancer treatments for patients who had very few options. ACT utilizes the patient’s own immune system to attack cancer cells.

 

Therapeutic Targets: Engineered TCR therapy is a type of ACT that leverages engineered T cell receptors to target tumor-specific antigens. The process starts with sequencing the tumor biopsy to identify tumor mutations and typically the peripheral blood to uncover the TCR repertoire.

 

TCR repertoire sequencing can be done via single-cell sequencing or bulk sequencing. Each has its own advantages. Bulk sequencing allows sampling of more of the sequence space, but information about alpha-beta TCR pairing is lost. Single-cell sequencing captures information on alpha-beta chain pairing and receptor composition but has a much lower throughput than bulk sequencing.

 

Modern therapeutic targets are becoming more challenging, and traditional single-modality platforms are no longer sufficient on their own. Twist Bioscience Solutions is the union of two of the industry’s best antibody discovery service providers, together offering partners the ‘discovery trifecta’ – in vivo, in vitro, and in silico antibody discovery all under one roof.

 

Twist Biopharma Solutions, or TBS, offers one-of-a-kind discovery services, providing partners with improved diversity, enhanced screening, and ultra-fast lead selection and engineering, which can mean a faster path in the race to the clinic.

 

How Twist Bioscience Makes an Impact

 

Emily has been a phenomenal driving force behind the company. As an early pioneer in high-throughput synthesis and sequencing of DNA, Dr. Leproust is disrupting markets to enable the exponential growth of DNA-based applications including chemicals and materials, diagnostics, therapeutics, food, and digital data storage. In 2020, BIO presented her with the Rosalind Franklin Award for Leadership. Foreign Policy named her one of their 100 Leading Global Thinkers, and Fast Company named her one of the Most Creative People in Business. Prior to Twist Bioscience, she held escalating positions at Agilent Technologies, where she architected the successful SureSelect product line that lowered the cost of sequencing and elucidated mechanisms responsible for dozens of Mendelian diseases.

 

In the scheme of things at Twist Bioscience, it becomes important to understand how Twist builds TCR libraries and the role of the Combinatorial TCR Library. Twist enables shuffling of alpha and beta chain pairs to create additional diversity and explore novel combinations beyond the identified repertoire. This approach complements bulk sequencing, where alpha-beta TCR pairing is unknown.